Stock Alert: RedHill Biopharma Shares Soar In Pre-Market

(RTTNews) - RedHill Biopharma Ltd. (RDHL) shares are rising above 5% in pre-market today, after the company said it is actively pursuing an exploratory program intended to evaluate the activity of opaganib and RHB-107, individually and in combination with hydroxychloroquine and other compounds in the treatment of COVID-19.

The company today provided an update on its clinical development programs for opaganib (Yeliva). RedHill noted that an investigator-sponsored Phase 2 study evaluating opaganib in prostate cancer has been initiated at the Medical University of South Carolina (MUSC) Hollings Cancer Center. The study is intended to evaluate the safety and efficacy of opaganib in patients with metastatic castration-resistant prostate cancer (mCRPC) that is progressing during treatment with androgen-signaling blockers abiraterone or enzalutamide.

Further, RedHill said it completed the enrollment of the full cohort of 39 patients evaluable for efficacy in the Phase 1/2a study evaluating the activity of orally-administered opaganib in patients suffering from advanced, unresectable intrahepatic, perihilar and extrahepatic cholangiocarcinoma.

RedHill is also pursuing an exploratory program of opaganib and RHB-107 individually and in combination with hydroxychloroquine and other compounds for the treatment of COVID-19 (novel coronavirus), based on pre-clinical data and literature indicating potential anti-viral activity.

The stock has been trading between $3.81 and $9.20 in the past one year, and closed Tuesday's trade at $4.35, up 13 cents or 3.08%. RDHL is currently trading at $4.60, up 25 cents or 5.75% in pre market.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2021    »